Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its ...

(Reuters) -U.S. drugmaker Pfizer reported first-quarter profit above Wall Street estimates on Tuesday, helped by cots cuts ...

Using the same arm for a booster vaccine as for a first dose may help the immune system respond effectively to a disease ...

Pfizer Inc (NYSE:PFE) kicks off its Q1 report before U.S. markets open on Tuesday, and investors are bracing for a bit of a ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and ...

Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...